Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8503
Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel
Ibanez, Borja CNIC | Aletras, Anthony H | Arai, Andrew E | Arheden, Hakan | Bax, Jeroen | Berry, Colin | Bucciarelli-Ducci, Chiara | Croisille, Pierre | Dall'Armellina, Erica | Dharmakumar, Rohan | Eitel, Ingo | Fernandez-Jimenez, Rodrigo CNIC | Friedrich, Matthias G | García-Dorado, David | Hausenloy, Derek J | Kim, Raymond J | Kozerke, Sebastian | Kramer, Christopher M | Salerno, Michael | Sánchez-González, Javier | Sanz, Javier CNIC | Fuster, Valentin CNIC
J Am Coll Cardiol. 2019, 74(2): 238-256
After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.
STEMI | area at risk | clinical trial | edema | endpoint | infarct size | magnetic resonance imaging | myocardial infarction
Files in this item
- CardiacMRIEndpointsMyocardial_ ...